Translational Genomics Research Institute
 | This article contains promotional content. (March 2020) |
33°27′10.68″N 112°4′1.83″W / 33.4529667°N 112.0671750°W
| Company type | Research Institute |
|---|---|
| Industry | Genomics |
| Founded | July 2002, Phoenix, Arizona, United States |
| Headquarters | Phoenix, Arizona, United States |
Key people | Jeffrey Trent[1] |
| Revenue | |
Number of employees | 258 (2008)[2] |
| Website | www |
The Translational Genomics Research Institute (TGen) is a non-profit genomics research institute based in Phoenix, Arizona, United States.
History and activities
[edit]TGen was established in July 2002 by Jeffrey Trent in Phoenix, Arizona, with an initial investment of US$100 million from Arizona public- and private-sector investors.[2]
The field of translational genomics research searches for ways to apply results from the Human Genome Project to the development of improved diagnostics, prognostics, and therapies for cancer, neurological disorders, diabetes and other complex diseases.
The mission of TGen is to make and translate genomic discoveries into advances in human health.[3] TGen has contributed to the growth of scientific research and biotechnology in Arizona. The institute has been involved in collaborations and studies, such as the research on chronic traumatic encephalopathy (CTE) in former NFL players in partnership with Exosome Sciences.[4]
References
[edit]- ^ "Administrative leadership". Tgen. Retrieved April 8, 2024.
- ^ a b c d Alltucker, Ken (16 April 2008). "5-year-old TGen fights for funding". The Arizona Republic. Archived from the original on 17 January 2013.
- ^ Alltucker, Ken (16 April 2008). "Cancer-drug trials show promise". The Arizona Republic. Archived from the original on 17 January 2013.
- ^ "Exosome Sciences, TGen to Launch Study of CTE in Former NFL Players". CellOMICs. 26 March 2018. Retrieved 27 March 2018.
